Antimicrobial Agents and Chemotherapy · 2008 · 21 citations · 23 references
PharmacyInfectious DiseasesPharmacologyImmunopharmacologyMolecular VirologyVirologyAntiviral AgentsAntiviral PharmacologyAntiviral PharmacotherapyAntiviral TherapyInterferon-based TherapyViral ClearanceBovine Viral Diarrhea VirusCombination Drug TherapyCombination TherapyDrug Combination TherapyDual Therapy RegimensRibavirin TherapyTriple Combination TherapyTriple Therapy Regimens
We evaluated interferon (IFN) and ribavirin (RBV) as dual therapy and as part of triple-combination therapies with the iminosugars N-butyl-deoxynojirimycin (NB-DNJ), N-nonyl-deoxynojirimycin, and N-7-oxanonyl-6-deoxymethyl-galactonojirimycin. The ability of these compounds to clear bovine viral diarrhea virus (BVDV), a surrogate model for hepatitis C virus (HCV), from a persistently infected Madin-Darby bovine kidney cells cell line was determined by monitoring the secretion of viral RNA and the infectivity of secreted virions. In the BVDV system, after treatment with IFN-RBV alone, viral rebound was observed immediately after removal of the drugs. In contrast, we demonstrate that a triple drug combination of IFN, RBV, and an iminosugar eradicated the BVDV infection in a time- and a dose-dependent manner, leading to sustained viral clearance. Importantly, in the case of NB-DNJ, the sustained viral clearance was achieved by using physiologically relevant and tolerated drug concentrations. Therefore, the use of a triple-combination therapy that includes an iminosugar may prove to be of greater therapeutic value for the treatment of HCV infection than the use of IFN-RBV alone.
23
Complete Replication of Hepatitis C Virus in Cell Culture
Brett D. Lindenbach, Matthew J. Evans, Andrew J. Syder et al. · Science · 2005 · 2.2K citations
Robust hepatitis C virus infection <i>in vitro</i>
Jin Zhong, Pablo Gastaminza, Guofeng Cheng et al. · Proceedings of the National Academy of Sciences · 2005 · 1.7K citations